Our data show that measurement of plasma IP-10 and VEGF concentrations could be a valuable adjunct to monitor TB treatment, and suggest that persistently elevated VEGF and/or IP-10 levels may reflect inefficient therapy or lack of treatment compliance. This evidence concerns the gene VEGFA and tuberculosis.